MONOPAR THERAPEUTICS INC (MNPR)

Company Profile

Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. The company is headquartered in Wilmette, Illinois and currently employs 11 full-time employees. The company went IPO on 2019-12-19. The firm's pipeline consists of Validive, camsirubicin, MNPR-101, MNPR-101 RIT and MNPR-202. Its lead product candidate, Validive is under Phase IIb/III clinical trial for the prevention of chemoradiotherapy (CRT)-induced severe oral mucositis (SOM) in patients with oropharyngeal cancer (VOICE trial). The firm also commenced a United States-based open-label, Phase Ib clinical trial of camsirubicin for the treatment of advanced soft tissue sarcoma (ASTS). Its three preclinical programs include MNPR-101, MNPR-101 RIT and MNPR-202. Its MNPR-101 is a humanized monoclonal antibody to the urokinase plasminogen activator receptor (uPAR), for use as a radiopharmaceutical in advanced cancers. Its MNPR-101 RIT which continues development for the treatment of cancer and severe COVID-19 in collaboration.

Company Info

MONOPAR THERAPEUTICS INC

1000 Skokie Blvd Ste 350

Wilmette ILLINOIS 60091

P: 18473880349

CEO: Chandler Robinson

Employees: 11

Website: https://www.monopartx.com/